Free Trial

Edgestream Partners L.P. Has $2.06 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences logo with Medical background

Edgestream Partners L.P. increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 99.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,401 shares of the biopharmaceutical company's stock after purchasing an additional 9,152 shares during the period. Edgestream Partners L.P.'s holdings in Gilead Sciences were worth $2,062,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Brighton Jones LLC increased its position in Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after purchasing an additional 2,450 shares in the last quarter. Proficio Capital Partners LLC acquired a new position in Gilead Sciences during the fourth quarter worth $339,000. OVERSEA CHINESE BANKING Corp Ltd acquired a new position in Gilead Sciences during the fourth quarter worth $670,000. VSM Wealth Advisory LLC purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at about $69,000. Finally, Grey Fox Wealth Advisors LLC purchased a new stake in Gilead Sciences during the fourth quarter worth about $211,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the transaction, the insider owned 121,152 shares in the company, valued at approximately $13,026,263.04. This represents a 18.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction that occurred on Monday, June 30th. The shares were sold at an average price of $110.45, for a total value of $1,104,500.00. Following the transaction, the chief executive officer owned 615,725 shares in the company, valued at $68,006,826.25. This trade represents a 1.60% decrease in their position. The disclosure for this sale can be found here. Insiders sold 72,000 shares of company stock worth $7,844,775 over the last ninety days. Company insiders own 0.27% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price target on the stock. Oppenheimer decreased their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. JPMorgan Chase & Co. lifted their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Finally, Morgan Stanley upped their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Nine analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of "Moderate Buy" and an average price target of $111.38.

View Our Latest Analysis on Gilead Sciences

Gilead Sciences Trading Down 1.0%

NASDAQ:GILD opened at $108.80 on Friday. The stock has a market capitalization of $135.34 billion, a price-to-earnings ratio of 22.91, a PEG ratio of 0.71 and a beta of 0.29. The firm has a fifty day simple moving average of $108.58 and a two-hundred day simple moving average of $105.06. Gilead Sciences, Inc. has a 12 month low of $70.78 and a 12 month high of $119.96. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The company had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. During the same quarter in the previous year, the company earned ($1.32) earnings per share. Gilead Sciences's revenue for the quarter was down .3% on a year-over-year basis. Analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.90%. The ex-dividend date of this dividend was Friday, June 13th. Gilead Sciences's payout ratio is 66.53%.

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Featured Articles

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Gilead Sciences Right Now?

Before you consider Gilead Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.

While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
This Strategy Beat the S&P—And Most Investors Ignore It
NVDA Greenlight: China Sales Spark 50% Rally Potential

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines